Kenichi Shimada

8PUBLICATIONS
8CO-AUTHORS
Molecular targetsPredictive and prognostic markersCarbon capture engineering (excl. sequestration)Molecular medicine
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Sep 24, 2026
TALAVE in Breast Cancer: BRCA1/2 Mutation-Dependent Immune Remodeling after PARP Inhibition with Limited Checkpoint Engagement.

|Sep 18, 2025
APOE+ Tumor-Associated Macrophages and CD4-DOCK4 T Cells Reveal Distinct Microenvironmental Features in HER2-Low and HER2-0 Hormone Receptor-Positive Breast Cancer.

Carlos Wagner S Wanderley, Daniel E Michaud, Kenichi Shimada

|Dec 09, 2024
An estrogen receptor signaling transcriptional program linked to immune evasion in human hormone receptor-positive breast cancer.

Kenichi Shimada, Daniel E Michaud, Yvonne Xiaoyong Cui

|May 06, 2021
Publisher Correction: Colchicine acts selectively in the liver to induce hepatokines that inhibit myeloid cell activation.

Jui-Hsia Weng, Peter David Koch, Harding H Luan

|Apr 13, 2021
Colchicine acts selectively in the liver to induce hepatokines that inhibit myeloid cell activation.

Jui-Hsia Weng, Peter David Koch, Harding H Luan

|Feb 08, 2021
shinyDepMap, a tool to identify targetable cancer genes and their functional connections from Cancer Dependency Map data.

Kenichi Shimada, John A Bachman, Jeremy L Muhlich

Pageof 2

Frequent Collaborators

3 joint publications

Timothy J Mitchison

2 joint publications

Jeremy L Muhlich

2 joint publications

Jui-Hsia Weng

2 joint publications

Jennifer L Guerriero